Wetherby Asset Management Inc Catalent, Inc. Transaction History

Wetherby Asset Management Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$45.44 - $74.26 $46,803 - $76,487	1,030 Added 13.04%	8,931 $586,000
Q4 2022 Feb 14, 2023	BUY	$41.39 - $81.0 $106,827 - $209,061	2,581 Added 48.52%	7,901 $355,000
Q3 2022 Nov 14, 2022	SELL	$72.36 - $113.1 $42,837 - $66,955	-592 Reduced 10.01%	5,320 $385,000
Q2 2022 Aug 15, 2022	BUY	$87.2 - $114.05 $77,520 - $101,390	889 Added 17.7%	5,912 $634,000
Q1 2022 May 16, 2022	BUY	$94.19 - $124.49 $22,888 - $30,251	243 Added 5.08%	5,023 $557,000
Q4 2021 Feb 14, 2022	BUY	$119.57 - $139.07 $1,673 - $1,946	14 Added 0.29%	4,780 $612,000
Q3 2021 Nov 15, 2021	BUY	$109.17 - $142.35 $10,807 - $14,092	99 Added 2.12%	4,766 $634,000
Q2 2021 Aug 16, 2021	BUY	$100.34 - $115.69 $468,286 - $539,925	4,667 New	4,667 $505,000
Q1 2021 May 14, 2021	SELL	$101.51 - $125.27 $435,477 - $537,408	-4,290 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$85.88 - $105.36 $1,116 - $1,369	13 Added 0.3%	4,290 $446,000
Q3 2020 Nov 13, 2020	BUY	$72.74 - $92.5 $311,108 - $395,622	4,277 New	4,277 $366,000

514

149M

575K

2.03M

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $10.9B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Wetherby Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Wetherby Asset Management Inc with notifications on news.